$75,000 of DEXCOM lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"continuous glucose monitoring continuous glucose monitoring"
You can find more data on corporate lobbying on Quiver Quantitative.
DXCM Congressional Stock Trading
Members of Congress have traded $DXCM stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:
- SENATOR JOHN BOOZMAN purchased up to $15,000 on 01/26.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
DXCM Insider Trading Activity
DXCM insiders have traded $DXCM stock on the open market 8 times in the past 6 months. Of those trades, 2 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:
- JACOB STEVEN LEACH (President & COO) has made 2 purchases buying 18,200 shares for an estimated $1,001,701 and 0 sales.
- RICHARD ALEXANDER COLLINS has made 0 purchases and 2 sales selling 6,854 shares for an estimated $389,410.
- MICHAEL JON BROWN (EVP, Chief Legal Officer) has made 0 purchases and 2 sales selling 3,400 shares for an estimated $217,413.
- BRIDGETTE P HELLER has made 0 purchases and 2 sales selling 2,024 shares for an estimated $127,592.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DXCM Hedge Fund Activity
We have seen 476 institutional investors add shares of DXCM stock to their portfolio, and 442 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 21,931,067 shares (-73.3%) from their portfolio in Q4 2025, for an estimated $1,455,564,916
- ALLIANCEBERNSTEIN L.P. added 8,204,553 shares (+1955.4%) to their portfolio in Q4 2025, for an estimated $544,536,182
- CITADEL ADVISORS LLC removed 6,691,590 shares (-98.7%) from their portfolio in Q4 2025, for an estimated $444,120,828
- SANDS CAPITAL MANAGEMENT, LLC removed 4,934,189 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $327,482,123
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 4,815,048 shares (-85.9%) from their portfolio in Q4 2025, for an estimated $319,574,735
- JENNISON ASSOCIATES LLC removed 4,300,430 shares (-42.6%) from their portfolio in Q4 2025, for an estimated $285,419,539
- WELLINGTON MANAGEMENT GROUP LLP added 2,994,303 shares (+3777.3%) to their portfolio in Q4 2025, for an estimated $198,731,890
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DXCM Analyst Ratings
Wall Street analysts have issued reports on $DXCM in the last several months. We have seen 11 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/13/2026
- Barclays issued a "Underweight" rating on 01/12/2026
- Mizuho issued a "Outperform" rating on 12/17/2025
- Argus Research issued a "Buy" rating on 11/07/2025
- UBS issued a "Buy" rating on 11/03/2025
- Piper Sandler issued a "Overweight" rating on 10/31/2025
- RBC Capital issued a "Outperform" rating on 10/31/2025
To track analyst ratings and price targets for DXCM, check out Quiver Quantitative's $DXCM forecast page.
DXCM Price Targets
Multiple analysts have issued price targets for $DXCM recently. We have seen 17 analysts offer price targets for $DXCM in the last 6 months, with a median target of $85.0.
Here are some recent targets:
- Joanne Wuensch from Citigroup set a target price of $84.0 on 03/11/2026
- Marie Thibault from BTIG set a target price of $85.0 on 03/09/2026
- Richard Newitter from Truist Securities set a target price of $80.0 on 02/17/2026
- Anthony Petrone from Mizuho set a target price of $90.0 on 02/13/2026
- Matt Miksic from Barclays set a target price of $72.0 on 02/13/2026
- Larry Biegelsen from Wells Fargo set a target price of $85.0 on 02/13/2026
- William Plovanic from Canaccord Genuity set a target price of $95.0 on 02/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
